A detailed history of Group One Trading, L.P. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 201,294 shares of VKTX stock, worth $14.7 Million. This represents 0.35% of its overall portfolio holdings.

Number of Shares
201,294
Previous 74,245 171.12%
Holding current value
$14.7 Million
Previous $6.09 Million 75.26%
% of portfolio
0.35%
Previous 0.23%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$47.39 - $80.2 $6.02 Million - $10.2 Million
127,049 Added 171.12%
201,294 $10.7 Million
Q1 2024

May 10, 2024

BUY
$17.4 - $94.5 $892,967 - $4.85 Million
51,320 Added 223.86%
74,245 $6.09 Million
Q4 2023

Feb 14, 2024

SELL
$9.24 - $19.64 $4.66 Million - $9.91 Million
-504,536 Reduced 95.65%
22,925 $426,000
Q3 2023

Nov 09, 2023

BUY
$10.92 - $16.0 $349,068 - $511,456
31,966 Added 6.45%
527,461 $5.84 Million
Q2 2023

Aug 09, 2023

SELL
$14.84 - $24.79 $303,581 - $507,129
-20,457 Reduced 3.96%
495,495 $8.03 Million
Q1 2023

May 12, 2023

SELL
$8.08 - $17.33 $1.91 Million - $4.09 Million
-235,959 Reduced 31.38%
515,952 $8.59 Million
Q4 2022

Feb 09, 2023

BUY
$2.72 - $9.4 $1.64 Million - $5.68 Million
604,295 Added 409.37%
751,911 $7.07 Million
Q3 2022

Nov 09, 2022

BUY
$2.55 - $3.89 $67,467 - $102,921
26,458 Added 21.84%
147,616 $402,000
Q2 2022

Aug 11, 2022

BUY
$2.11 - $3.15 $2,561 - $3,824
1,214 Added 1.01%
121,158 $350,000
Q1 2022

May 12, 2022

BUY
$3.0 - $4.88 $91,584 - $148,976
30,528 Added 34.14%
119,944 $360,000
Q4 2021

Feb 11, 2022

BUY
$4.6 - $6.72 $76,594 - $111,894
16,651 Added 22.88%
89,416 $411,000
Q3 2021

Nov 12, 2021

BUY
$5.58 - $7.04 $53,562 - $67,576
9,599 Added 15.2%
72,765 $457,000
Q2 2021

Aug 10, 2021

SELL
$5.19 - $6.73 $31,695 - $41,100
-6,107 Reduced 8.82%
63,166 $378,000
Q1 2021

May 12, 2021

SELL
$5.74 - $9.67 $1.48 Million - $2.5 Million
-258,124 Reduced 78.84%
69,273 $438,000
Q4 2020

Feb 10, 2021

BUY
$5.3 - $6.71 $998,853 - $1.26 Million
188,463 Added 135.65%
327,397 $1.84 Million
Q3 2020

Nov 12, 2020

BUY
$5.73 - $8.11 $60,411 - $85,503
10,543 Added 8.21%
138,934 $809,000
Q2 2020

Aug 13, 2020

SELL
$4.35 - $8.08 $5,755 - $10,689
-1,323 Reduced 1.02%
128,391 $926,000
Q1 2020

May 13, 2020

BUY
$3.45 - $7.95 $395,511 - $911,395
114,641 Added 760.57%
129,714 $607,000
Q4 2019

Feb 10, 2020

SELL
$6.38 - $8.73 $678,583 - $928,531
-106,361 Reduced 87.59%
15,073 $121,000
Q3 2019

Nov 12, 2019

BUY
$6.55 - $8.6 $581,771 - $763,852
88,820 Added 272.34%
121,434 $835,000
Q2 2019

Aug 09, 2019

SELL
$7.67 - $10.63 $327,278 - $453,582
-42,670 Reduced 56.68%
32,614 $271,000
Q1 2019

May 13, 2019

SELL
$7.58 - $9.94 $909,509 - $1.19 Million
-119,988 Reduced 61.45%
75,284 $748,000
Q4 2018

Feb 06, 2019

SELL
$7.16 - $16.21 $1.69 Million - $3.83 Million
-236,241 Reduced 54.75%
195,272 $1.49 Million
Q3 2018

Nov 08, 2018

BUY
$9.7 - $19.65 $2.49 Million - $5.04 Million
256,658 Added 146.78%
431,513 $7.52 Million
Q2 2018

Aug 14, 2018

BUY
$3.88 - $12.74 $566,076 - $1.86 Million
145,896 Added 503.8%
174,855 $1.66 Million
Q1 2018

May 11, 2018

BUY
$4.11 - $6.93 $119,021 - $200,685
28,959 New
28,959 $127,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $5.59B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.